Skip to main navigation
Kyverna Therapeutics Logo
  • Overview
  • News Releases
  • Events & Presentations
  • Governance
    • Governance Overview
    • Board of Directors
    • Leadership Team
    • Committee Composition
  • Financials
    • SEC Filings
  • Stock
    • Stock Quote & Chart
    • Analyst Coverage
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR
    • Educational Videos

Investor Relations

Minimum 15 minutes delayed. Source: LSEG

Our Mission

Our Mission

Liberating autoimmune patients through the curative potential of cell therapy.

Read More
Kyverna

Corporate Presentation

Investor Presentation – March 2026

KYSA-8 Topline Results for Stiff Person Syndrome

Neuroimmunology CAR T Franchise KOL Event Presentation - August 2025

Educational Videos

Expand your knowledge about CAR T-cell therapies and autoimmune diseases from scientist and patient perspectives. View here

News Releases

Press Releases

March 26, 2026
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
March 5, 2026
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
March 3, 2026
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
February 24, 2026
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
View All News

Investor Contact

drafts InvestorRelations@kyvernatx.com
drafts Media@kyvernatx.com
phone_iphone +1 510.925.2492
© 2026 Kyverna Therapeutics

Social Media

  • LinkedIn opens in new window
  • Glassdoor opens in new window
Search Investors